Transforming global health with purposeful innovation
About us
Our commitment to Global Health
Medincell’s core mission is to enhance and safeguard the health of people worldwide. We believe in the equitable distribution of the value we create, ensuring all our employees are recognized and rewarded. This principle underpins our business model and is crucial to Medincell’s enduring success, enabling us to steadfastly pursue our goals.
How we make a difference in addressing global health challenges
Improving treatment adherence
According to the World Health Organization, half of all patients either don’t initiate or discontinue their prescribed treatments. Enhancing adherence is pivotal and could surpass any medical advancements in treatment. By focusing on this aspect, we aim to transform patient outcomes significantly.
Enhancing treatment accessibility
Our cutting-edge technologies, when combined with our inclusive “Global Access” initiative, are designed to provide equitable treatment options for individuals around the world, irrespective of their financial means or healthcare systems.
Minimizing environmental impact
We are committed to reducing pharmaceutical residues, a pressing ecological concern. Our technologies strive to minimize the active ingredients required for treatments and prevent pharmaceutical waste from bypassing recycling processes.
Our approach to realizing our vision
Patient-centric collaboration
Collaboration is the essence of our approach. To offer novel therapeutic solutions globally, we’ve cultivated a network of esteemed partners, encompassing industry experts, academic researchers, and leading foundations.
Value sharing
We advocate for employee share ownership, promoting the equitable distribution of generated value. This fosters a harmonious dynamic between our management and staff, aligning the interests of all stakeholders — employees, shareholders, and partners alike.
Diversity and workplace well-being
Our strength lies in our diverse and gifted team. We are dedicated to maintaining a nurturing and respectful work environment, as the well-being of our team is a top priority.
Our strength lies in our people
Since Medincell’s inception, the expertise and dedicated engagement of our team have been vital to our growth. To share our achievements and maintain our collective aspiration of ‘positively impacting health,’ we ensure that all employees become shareholders shortly after joining us. This practice of involving all collaborators early in our success has fostered an entrepreneurial spirit across every level of the organization.
Medincell in one word
Join the team
Unleash your entrepreneurial spirit within a creative and innovative team of international experts dedicated to tackling global health challenges.
Leadership team
Our commitment transcends our core objectives, it is a pledge to serve not only patients worldwide but also to support our dedicated team and to align the interests of all Medincell stakeholders.
Management team
Christophe Douat
CEO
Richard Malamut, MD
Chief Medical Officer
Sébastien Enault
Chief Business Officer
Julie Alimi
General Counsel and Chief Corporate Development Officer
Philippe Moyen
Chief Operating Officer
Grace Kim
Chief Strategy Officer, U.S. Finance
Stéphane Postic
CFO
Franck Pouzache
Chief People Officer
Adolfo Lopez-Noriega
Head of R&D
Quiterie de Beauregard
Head of Global Health Development
David Heuzé
Head of Corporate & Financial Communications, and ESG
Board of Directors
Philippe Guy spent more than 30 years at Boston Consulting Group (BCG), where he built deep global expertise in biopharma and medtech consulting across Europe (London, Paris, Zurich), Japan, and the United States. He played a central role in expanding BCG’s Healthcare Practice, ultimately serving as Global Leader of the Healthcare Practice (1997–2006) and later representing all sector and functional practices on BCG’s Global Executive Committee.
Throughout his career, Philippe has advised leading pharmaceutical, biotechnology, and medical device companies on corporate and business unit strategy, R&D optimization, commercial models, large scale transformations, and post merger integration. He continues to bring this experience to industry through board roles, including serving on the board of Moleac, a Singapore based company focused on therapies for neurological recovery.
He is also deeply engaged in sustainability and ocean preservation, working pro bono with the Fondation de la Mer to support its international expansion, contribute to key UN negotiations, and facilitate the creation of the Alliance for European Seas.
A graduate of HEC Paris, Philippe is recognized for his combination of operational and strategic leadership in healthcare, his commitment to value creation and sustainable transformation, and his long standing dedication to ESG at the highest governance levels.
Throughout his career, Philippe has advised leading pharmaceutical, biotechnology, and medical device companies on corporate and business unit strategy, R&D optimization, commercial models, large scale transformations, and post merger integration. He continues to bring this experience to industry through board roles, including serving on the board of Moleac, a Singapore based company focused on therapies for neurological recovery.
He is also deeply engaged in sustainability and ocean preservation, working pro bono with the Fondation de la Mer to support its international expansion, contribute to key UN negotiations, and facilitate the creation of the Alliance for European Seas.
A graduate of HEC Paris, Philippe is recognized for his combination of operational and strategic leadership in healthcare, his commitment to value creation and sustainable transformation, and his long standing dedication to ESG at the highest governance levels.
Elisabeth Kogan is the Co Founder and Chief Executive Officer of Syremis Therapeutics, a clinical stage biopharmaceutical company developing next generation treatments for mental health disorders. Founded in 2025, the company launched with a $165 million Series A financing led by top global investors including Dexcel Pharma, Third Rock Ventures, Bain Capital, and GV (Google Ventures).
Elisabeth brings more than 20 years of leadership experience in the pharmaceutical industry, with senior roles spanning innovation, global R&D, portfolio strategy, and commercial operations. Before Syremis, she co founded and served as CEO of Clexio Biosciences, and held multiple executive positions at Teva Pharmaceuticals, including SVP InnoTech, SVP Global Generic R&D, and VP Global Portfolio Strategy.
She has extensive experience leading international teams and advancing breakthrough technologies from concept to implementation. Elisabeth also serves as a Board Member at MedinCell and previously sat on the board of École Polytechnique. She holds a Master of Science in Science and Engineering from CentraleSupélec.
Elisabeth brings more than 20 years of leadership experience in the pharmaceutical industry, with senior roles spanning innovation, global R&D, portfolio strategy, and commercial operations. Before Syremis, she co founded and served as CEO of Clexio Biosciences, and held multiple executive positions at Teva Pharmaceuticals, including SVP InnoTech, SVP Global Generic R&D, and VP Global Portfolio Strategy.
She has extensive experience leading international teams and advancing breakthrough technologies from concept to implementation. Elisabeth also serves as a Board Member at MedinCell and previously sat on the board of École Polytechnique. She holds a Master of Science in Science and Engineering from CentraleSupélec.
Dr. Charles Kunsch is a seasoned life sciences executive and investor with over 30 years of leadership in R&D, venture capital, and biotech innovation. He served as Managing Director at AbbVie Ventures, where he led investments in many high-impact biotech companies including Prevail Therapeutics (acquired by Lilly) and Tidal Therapeutics (acquired by Sanofi) among others. Earlier in his career, he held senior scientific roles at AbbVie, AtheroGenics and Human Genome Sciences. Charles Kunsch holds a Ph.D. in Immunology from Pennsylvania State University College of Medicine and completed postdoctoral training at the Roche Institute of Molecular Biology. He currently serves as a Venture Partner at Dreavent Capital, Vice-Chair of the Board at Massachusetts Biomedical Initiatives, Board of Trustees of the Penn State Research Foundation, and is a board member at Captor Therapeutics and Antiverse.
Tone Kvåle is the Chief Financial Officer of Herantis Pharma, bringing more than 25 years of leadership experience in the biotech and life sciences industry. She previously served for seven years as CFO of Nordic Nanovector, a publicly listed Norwegian biotechnology company, and has held CFO roles at NorDiag, Kavli Holding, and Dynal Biotech, alongside senior management positions at Invitrogen/Life Technologies in the United States, now part of Thermo Fisher.
Throughout her career, Tone has played a central role in raising over EUR 200 million in financing, and has been actively involved in IPOs and M&A transactions. She has overseen financial reporting under several regulatory frameworks, including US GAAP and IFRS. She also served as a board director and Chair of the Audit Committee of Bonesupport AB (BONEX) in Sweden from 2016 to 2022.
Tone holds a diploma in finance and administration from UiT – The Arctic University of Norway, Harstad, and has completed the prescribed course of study and examinations required for her field.
Throughout her career, Tone has played a central role in raising over EUR 200 million in financing, and has been actively involved in IPOs and M&A transactions. She has overseen financial reporting under several regulatory frameworks, including US GAAP and IFRS. She also served as a board director and Chair of the Audit Committee of Bonesupport AB (BONEX) in Sweden from 2016 to 2022.
Tone holds a diploma in finance and administration from UiT – The Arctic University of Norway, Harstad, and has completed the prescribed course of study and examinations required for her field.
Dr. Sabri Markabi is a neuroscience specialist and pharmacologist with more than 25 years of international leadership experience in the pharmaceutical industry. He led major R&D and clinical organizations at Novartis, heading the Global Neurosciences Therapeutic Area and later overseeing ophthalmics development as VP and Global Head of Development for the Ophthalmics Business Unit.
From 2008 to 2015, he served as Senior Vice President, Global Head of R&D and Chief Medical Officer at Alcon, directing global development programs and regulatory strategy across multiple ophthalmic indications. Throughout his career, he has participated in and chaired numerous corporate governance bodies in both private and publicly traded companies. -
Since 2015, Dr. Markabi has served as a consultant and board advisor, supporting healthcare companies on investment strategy and R&D direction. He currently operates through Health R&D LLC, providing strategic guidance to biopharma innovators.
From 2008 to 2015, he served as Senior Vice President, Global Head of R&D and Chief Medical Officer at Alcon, directing global development programs and regulatory strategy across multiple ophthalmic indications. Throughout his career, he has participated in and chaired numerous corporate governance bodies in both private and publicly traded companies. -
Since 2015, Dr. Markabi has served as a consultant and board advisor, supporting healthcare companies on investment strategy and R&D direction. He currently operates through Health R&D LLC, providing strategic guidance to biopharma innovators.
Christophe Douat is the Chief Executive Officer of MedinCell, a role he has held since joining the company in 2009. A former consultant at the Boston Consulting Group, he later served as an Investment Director at Matignon Investissement & Gestion, focusing on healthcare driven venture capital. He was also the lead investor and later an Independent Director at Nanobiotix, a pioneering nanomedicine company listed on Euronext.
Christophe spent 15 years in North America, where he was notably an entrepreneur before returning to Europe to take on leadership roles in healthcare innovation and corporate development. At MedinCell, he previously served as Chairman & Head of Corporate Development, contributing to the company’s strategic growth and international expansion.
He holds an engineering degree from École des Mines de Paris, a Master’s degree from the University of Minnesota, and an MBA from the University of Calgary, strengthening his multidisciplinary approach to science driven entrepreneurship and global business leadership.
Christophe spent 15 years in North America, where he was notably an entrepreneur before returning to Europe to take on leadership roles in healthcare innovation and corporate development. At MedinCell, he previously served as Chairman & Head of Corporate Development, contributing to the company’s strategic growth and international expansion.
He holds an engineering degree from École des Mines de Paris, a Master’s degree from the University of Minnesota, and an MBA from the University of Calgary, strengthening his multidisciplinary approach to science driven entrepreneurship and global business leadership.
Dr. Sharon Mates is the Co founder, Chairman, and CEO of Intra Cellular Therapies, which she established in 2002 with Nobel Laureate Dr. Paul Greengard, building on his pioneering research in intracellular signaling to advance novel treatments for psychiatric and neurologic disorders. She led the development and approval of CAPLYTA® (lumateperone), a breakthrough therapy for schizophrenia and bipolar depression, and guided the company through its IPO and growth to a valuation exceeding $10 billion, culminating in its $14.6 billion acquisition by Johnson & Johnson in April 2025.
Prior to founding Intra Cellular Therapies, Dr. Mates spent nearly a decade as President of North American Vaccine Inc., overseeing the development of pediatric vaccines. She holds a Ph.D. in anatomy and neuroscience and completed postdoctoral training at Harvard Medical School and Massachusetts General Hospital. Earlier in her career, she also held roles in scientific leadership, equity research, and investment banking within the life sciences sector, co founded several biotech companies, and served on multiple non profit boards.
Dr. Mates was named to Forbes’ “50 Over 50 – Innovation” list in recognition of her long standing impact on neuroscience and biotech innovation.
Prior to founding Intra Cellular Therapies, Dr. Mates spent nearly a decade as President of North American Vaccine Inc., overseeing the development of pediatric vaccines. She holds a Ph.D. in anatomy and neuroscience and completed postdoctoral training at Harvard Medical School and Massachusetts General Hospital. Earlier in her career, she also held roles in scientific leadership, equity research, and investment banking within the life sciences sector, co founded several biotech companies, and served on multiple non profit boards.
Dr. Mates was named to Forbes’ “50 Over 50 – Innovation” list in recognition of her long standing impact on neuroscience and biotech innovation.
Dr. Pascal Touchon is a seasoned biopharmaceutical executive with 40 years of international leadership experience, spanning strategic, operational, and board roles across the U.S. and Europe. He previously served as Global Head of Strategy and Business Development and later Global Head of Cell & Gene at Novartis Oncology, where he oversaw the unit’s global activities and led the development and launch of the first FDA approved cell and gene therapy in the U.S. (KYMRIAH®).
Pascal is the former CEO and Chairman of the Board of Atara Biotherapeutics, guiding the company through transformative stages of growth and innovation. He has also held leadership roles at Servier, Glaxo Wellcome, and Sanofi. Today, he serves as an Independent Director at Ipsen, CDR Life, and RoslinCT, and is an Operating Partner at Jeito Capital, supporting next generation biopharmaceutical companies.
Committed to advancing breakthrough science for patients with serious conditions, Pascal has built a career grounded in innovation, scientific rigor, and collaborative leadership. He holds a Doctorate in Veterinary Medicine from Paul Sabatier University and an MBA from INSEAD.
Pascal is the former CEO and Chairman of the Board of Atara Biotherapeutics, guiding the company through transformative stages of growth and innovation. He has also held leadership roles at Servier, Glaxo Wellcome, and Sanofi. Today, he serves as an Independent Director at Ipsen, CDR Life, and RoslinCT, and is an Operating Partner at Jeito Capital, supporting next generation biopharmaceutical companies.
Committed to advancing breakthrough science for patients with serious conditions, Pascal has built a career grounded in innovation, scientific rigor, and collaborative leadership. He holds a Doctorate in Veterinary Medicine from Paul Sabatier University and an MBA from INSEAD.
Virginie Lleu is a Senior Partner at WittKieffer, a leading global executive search and leadership advisory firm, recognized for its purpose‑driven culture, strong international footprint and deep expertise in healthcare, life sciences and organizations that improve quality of life.
She was previously a Senior Partner at Chaberton Partners Executive Search, following the integration of L3S Partnership, the life sciences executive search firm she founded and developed into a leading French boutique, to strengthen Chaberton’s international Healthcare & Life Sciences practice.
A clinical psychologist by training, she began her career as a neuropsychologist in Paris university hospitals before moving into talent leadership roles within the pharmaceutical industry and subsequently joining major global executive search firms, including Korn Ferry International and Spencer Stuart.
Virginie founded L2S in 2003, which was later acquired by Whitehead Mann, before launching L3S Partnership in 2010, establishing it as a reference firm in senior‑level Life Sciences recruitment across Europe.
She serves on the boards of La Fondation FondaMental and Medincell, and previously served on the board of LNC.
Virginie holds a post‑graduate degree (DESS) in Clinical Psychology and Pathology from the École des Psychologues Praticiens in Paris.
She was previously a Senior Partner at Chaberton Partners Executive Search, following the integration of L3S Partnership, the life sciences executive search firm she founded and developed into a leading French boutique, to strengthen Chaberton’s international Healthcare & Life Sciences practice.
A clinical psychologist by training, she began her career as a neuropsychologist in Paris university hospitals before moving into talent leadership roles within the pharmaceutical industry and subsequently joining major global executive search firms, including Korn Ferry International and Spencer Stuart.
Virginie founded L2S in 2003, which was later acquired by Whitehead Mann, before launching L3S Partnership in 2010, establishing it as a reference firm in senior‑level Life Sciences recruitment across Europe.
She serves on the boards of La Fondation FondaMental and Medincell, and previously served on the board of LNC.
Virginie holds a post‑graduate degree (DESS) in Clinical Psychology and Pathology from the École des Psychologues Praticiens in Paris.
